Prospective Observational Study on the Effectiveness of Daridorexant in Chronic Insomnia in a Real-World Setting

NCT07132086 · clinicaltrials.gov ↗

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Insomnia Chronic

Interventions

DRUG: Daridorexant 50 mg orally, once daily at bedtime, administered as monotherapy or add-on therapy for chronic insomnia, in a real-world, observational, prospective clinical setting

Sponsor

Azienda Ospedaliero, Universitaria Pisana